Biogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in a deal worth more than $2.1 billion.
The FDA has approved Ongentys, an oral Parkinson’s Disease drug from US biotech Neurocrine Biosciences, which can be added to prolong the effects of standard therapy and help prevent “off”
Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 bi
The FDA has approved a new drug for Parkinson’s disease, giving the nod to Kyowa Kirin’s Nourianz (istadefylline) as an add-on to dopamine replacement drugs to reduce “off” episodes when th
